TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05644860

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nanohybrid Compisite Group (Filtek Z250)
Description: Orthodontic brackets shall be bonded with Nano hybrid composite

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Composite Group (Transbond XT)
Description: Patients in which brackets will be bonded with conventional composite resin (Transbond XT)
Study: NCT05483634

Intervention type: DRUG
Intervention: Vaginal estrogen supplement
Description: Daily vaginal estrogen supplement, then twice per week. Continue for three months.

Intervention type: PROCEDURE
Intervention: Platelet-rich plasma injection
Description: Monthly platelet-rich plasma injection for three months
Study: NCT05560347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water application
Description: Hot application is applied by contacting any part of the body with a temperature of 40-45 degrees. Hot application stimulates the touch receptors and has a vasodilation effect. Thermoreceptors in the foot are stimulated by applying heat to the feet, and this stimulation is thought to be effective in reducing the activation of the sympathetic nervous system and thus reducing pain.
Study: NCT05045508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC-01 (varenicline 0.6mg/ml) nasal spray
Description: OC-01 nasal spray which contains varenicline is being developed by Oyster Point Pharma for the treatment of signs and symptoms of DED. OC-01 (varenicline) nasal spray activates the trigeminal parasympathetic pathway and stimulates natural tear production and bathe the corneal nerve endings in a protective layer of tear film. In addition, OC-01 (varenicline) acts as a cholinergic agonist and may provide analgesia by activating the trigeminal parasympathetic pathway.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) Nasal Spray
Description: Placebo (vehicle) nasal spray \[control\]
Study: NCT06202586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low FiO2
Description: FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 30% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 30% (2L oxygen +14L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 30% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high FiO2
Description: FiO2 was 100% in two-lung ventilation during anesthesia induction and one-lung ventilation stage intraoperative. FiO2 was 80% in two-lung ventilation after pulmonary reexpansion. During 2 hours after extubation, oxygen was administered through a non-reabsorption mask (high concentration oxygen mask; Intersurgical Ltd, Wokingham, UK) with a respiratory sac in the post anesthesia care unit (PACU), FiO2 was 80% (14L oxygen +2L air per minute). If the subjects who need to be admitted to the intensive care unit (ICU) fail to resuscitate the extubation within a short time after surgery due to their condition and require prolonged respiratory support, FiO2 should be adjusted to 80% 2 hours after admission to the ICU, and respiratory support according to the routine ventilation strategy of ICU should be provided 2 hours later.
Study: NCT05515380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8-stage model based exercise program
Description: The experimental group would follow exercises related to 8 phases of tennis serve, which would be based on 8-stage model. The participants would follow this program for three days per week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercise program
Description: The control group would follow conventional exercise program advised by coaches. The participants of this group would also follow this program for three days per week for 12 weeks.
Study: NCT04670588

Intervention type: DIAGNOSTIC_TEST
Intervention: Circulating tumor DNA(ctDNA) level measurement
Description: The ctDNA level will be measured using the Signatera platform developed by Natera, Inc. Signatera is a patient-specific, tumor informed custom-built ctDNA monitoring assay.
Study: NCT06319014

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modes
Description: Moderate intensity aerobic exercise Moderate intensity resistance exercise Moderate intensity combination exercise
Study: NCT05751187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab was given as 200 milligrams (mg) via intravenous (IV) infusion over 30 minutes on Day 1 of each 21-day cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was given as 15 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was given as 500 mg/m\^2 via intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle for 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was given as 75 mg/m\^2 via intravenous (IV) infusion (administered approximately 30 minutes after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given as Aare Under the Curve (AUC) 5 (5 mg/mL/min; over 15-60 min) via intravenous (IV) infusion (administered immediately after pemetrexed infusion) on Day 1 of each 21-day cycle for 4-6 cycles.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given on the same day as pemetrexed administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, the day of, and the day after pemetrexed administration.
Study: NCT05689996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone-Based Agent
Description: Ozone-based eye drops as adjuvant therapy in microbial keratitis
Study: NCT04859907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clamp-like system
Description: Craniotomy closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Plates and screws
Description: Craniotomy closure
Study: NCT06169969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magnetic therapy
Description: Kegel exercises
Study: NCT05512884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speeded anomia therapy
Description: The speeded anomia therapy was introduced as RISP (Repeated, Increasingly Speeded Production) by Conroy et al. (2018). Participants are asked to name the picture presented to them before an auditory stimulus ('beep' sound) at the end of item presentation. In each session the allotted response time is gradually reduced. After an incorrect response, participants are asked to repeat the word three times.
Study: NCT05536401

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TE
Description: The P200TE Ophthalmoscope provides widefield Scanning Laser Ophthalmoscope (SLO) fundus imaging and Optical Coherence Tomography (OCT) imaging in one device.

Intervention type: DEVICE
Group type: OTHER
Intervention: Predicate Device
Description: The predicate device is an optical coherence tomography system intended for in vivo imaging, axial cross-sectional, three-dimensional imaging and measurement of anterior and posterior ocular structures.
Study: NCT04965818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib and Binimetinib
Description: Patients will receive futibatinib once daily in combination with binimetinib twice daily by oral administration on a 21-day cycle
Study: NCT05962060

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proprioceptive neuromuscular facilition
Description: PNF Proprioceptive Neuromuscular Facilitation (PNF) is a more advanced form of flexibility training. PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulator
Description: Electrical Muscle Stimulation (EMS), also known as neuromuscular electrical stimulation (NMES) or electromyo stimulation, is a protocol that elicits a muscle contraction using electrical impulses that directly stimulate your motor neurons.
Study: NCT05661643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide capsule
Description: Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
Study: NCT05510388

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: The patients receive oxygen flow of 6L/min for preoxygenation with an high-flow canular oxygenation device before losing of conscious. Then, the oxygen flow is adjusted to 60L/min with the oxygen concentration of 100% and the temperature of 37℃ until the end of procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula oxygenation
Description: The patients receive an oxygen flow of 6L/min for preoxygenation with a disposal regular nasal cannula until the end of procedure.
Study: NCT05876442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy.
Description: Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy.
Description: Patients will receive EPSW therapy at the area of the wrist for 5 minutes 1 time a week for 2 months.
Study: NCT06324604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX-101
Description: MTX-101 (bispecific CD8 Treg modulator)
Study: NCT05959954

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing (QST)
Description: Quantitative Sensory Testing (QST) is a non-invasive diagnostic method used to assess sensory dysfunction. The test evaluates individual thresholds and pain responses to different types of mechanical, thermal, and electrical stimuli. For this study, QST will be used to gather baseline sensory data for patients with carpal tunnel syndrome. This information will then be used to predict the progression to nociplastic pain over a one-year follow-up period.
Study: NCT04881981

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SCART radiation therapy
Description: We will deliver high dose radiation therapy using SCART method. Beam energies of 6Mv will be used. The high dose SCART therapy will be delivered using LINAC systems, as available and appropriate for each patient. The treatment plan used for each patient will be based on an analysis of the volumetric dose including DVH analyses of the PTV and critical normal structures.
Study: NCT05339984

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial hepatectomy (open approach)
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: liver transplantation
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portal vein embolization
Description: preoperative flow MRI + intraoperative measures of flow and pressures + pre/intra/post-procedural ultrasonographic flowmetry
Study: NCT04881604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Compression Wrap
Description: Delivery, adaptation and guidance for daily use of the Adjustable Compression Wrap. (Ready Wrap® allows for easy use because to be pre-molded system in inelastic material with self-adjusting compressible components according to the size and shape of the upper limb. Due to its compressive properties, it can be used as therapy to control lymphedema. The material composition is: 61% Nylon, 33% Polyurethane, 6% Elastane (Spandex)).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Sleeve
Description: Delivery, adaptation and guidance for daily use of the Compression sleeve. (Compression Sleeve is a mesh in the shape of a glove that provides compression on the fabrics needed to help control the volume of the limbs. Traditionally used for stage 2 of compressive therapy. The composition of the material is: 64% Nylon, 36% Elastane (Spandex) ).~The institutional protocol for the lymphedema control phase will be respected, in which the orthosis is used at home for the longest possible period, with only removal for bathing and sleeping; furthermore, skin care and therapeutic exercises for the upper limbs must be performed daily.
Study: NCT05801744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Operant conditioning
Description: In this training, individuals with post-stroke hemiparesis are trained to increase the amount of reciprocal inhibition in their paretic leg. By increasing the amount of reciprocal inhibition, the paretic ankle in people post-stroke may exhibit less foot drop.
Study: NCT05876442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy
Description: High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..
Study: NCT06342271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking training
Description: Participants will receive Nordic walking training (to walk with poles) for 12 weeks, 3x/week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free Walking training
Description: Participants will receive Free walking training (to walk without poles) for 12 weeks, 3x/week.
Study: NCT05552885

Intervention type: OTHER
Intervention: Evaluation
Description: The Standardized Mini Mental Test, The American National Institutes of Health Stroke Scale, the Figure of 8 Walk Test, the double-task octagonal gait test, the timed up-and-go test, the 10-meter walk test, and the modified four-square step test will be applied to the stroke patients.
Study: NCT04818333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: Phase 1 Drug: SHR-A1811 There are four pre-defined dose regimens . Subjects will be enrolled with an initial dose Phase 2 Drug: SHR-A1811 Doses will be determined from Phase 1
Study: NCT06244420

Intervention type: OTHER
Intervention: Clinical data review
Description: review the medical records, radiological imaging, and histological data of these patients
Study: NCT05876442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy
Description: High-intensity laser therapy at the area of the carpal bones for 5 minutes 2 times a week for two months..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Exercise Program
Description: 30 minutes of stretching exercise for the wrist and carpal region with the fingers flexed and extended. Followed by strengthening exercises for the wrist flexors, extensors, and radial and ulnar deviation muscles. Mobilizing exercise, tendon gliding exercise, and instructed to wear a wrist splint at night for two months.
Study: NCT05430360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT201
Description: Autologous tumor infiltrating lymphocyte injection
Study: NCT06336733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA
Description: On demand Anakinra 100 mg/j from the prodromal phase of the attack until 24 hours of remission (during 7 days maximum) + colchicine + on demand analgesics
Study: NCT05063825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple cognitive task intervention
Description: A memory cue followed by playing the computer game Tetris (on own smartphone) with mental rotation instructions for ca. 12 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention placebo
Description: A memory cue followed by listening to a podcast (on own smartphone) for ca. 12 minutes.
Study: NCT04260425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving of oatmeal made from low avenanthramides oats and water
Description: One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving of oatmeal made from low avenanthramides oats and water
Description: One serving size (40 grams dry weight) of low avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving of oatmeal made from high avenanthramides oats and water
Description: One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serving of oatmeal made from high avenanthramides oats and water
Description: One serving size (40 grams dry weight) of high avenanthramides oats flakes will be used to make oatmeal. One cup of water and a dash of salt (0.72 g) will be added into the treatment and microwaved on high for 3 minutes. It will be stirred before serving. Ingredients and cooking time will be consistently maintained throughout.
Study: NCT04690530

Intervention type: PROCEDURE
Intervention: mechanical ventilation
Description: mechanical vantilation will be performed

Intervention type: DRUG
Intervention: Sedation
Description: sedation wil be performed
Study: NCT05128994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: User-controlled FES system
Description: Wearable FES sleeve with non-invasive user controls
Study: NCT05163171

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire for conjugal violence prevalence
Study: NCT05688982

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General information provision
Description: Patients will receive information with general oral health and aSDoH resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Geographic information provision
Description: Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Geographic information provision
Description: Patients will receive information with geographically-proximate oral health and aSDoH resources based on a directory created by the study team.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Navigational assistance
Description: Patients will receive phone-based navigational assistance from the study navigator.